SGMT Sagimet Biosciences Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1400118 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.5%
ROA-26.0%
ROIC (approx.)-43.4%
Asset turnover—
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio6.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $39.05M | $38.44M |
| SG&A expense | $17.84M | $16.01M |
| Operating income | -$56.89M | -$54.45M |
| Income tax | $0 | $0 |
| Net income | -$51.04M | -$45.57M |
| EPS (basic) | -1.58 | -1.45 |
| EPS (diluted) | -1.58 | -1.45 |
| Weighted avg. shares (diluted) | 32.35M | 31.35M |
| Balance sheet | ||
| Cash & equivalents | $35.02M | $75.84M |
| Short-term investments | $78.10M | $75.41M |
| Current assets | $116.40M | $152.77M |
| Total assets | $116.48M | $160.26M |
| Current liabilities | $5.10M | $4.45M |
| Total liabilities | $5.10M | $4.45M |
| Shareholders' equity | $111.38M | $155.81M |
| Cash flow statement | ||
| Operating cash flow | -$45.65M | -$42.44M |
| Investing cash flow | $4.56M | -$61.68M |
| Financing cash flow | $275,000 | $104.82M |
| Stock-based compensation | $6.45M | $5.29M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.